# OnCo record palifermin (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/palifermin/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "palifermin" ;
  schema:name "Palifermin"@en ;
  schema:alternateName "Recombinant keratinocyte growth factor"@en, "rHuKGF"@en, "Kepivance" ;
  schema:description "Palifermin (Kepivance) is a growth factor injected for three days before and after high-dose chemotherapy and stem cell rescue to reduce the severe mouth ulcers (mucositis) that this treatment causes in people with blood cancers."@en ;
  schema:url <https://onco.cc/drugs/palifermin/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Palifermin> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=palifermin>, <https://www.cancer.gov/about-cancer/treatment/drugs/palifermin>, <https://www.ema.europa.eu/en/medicines/human/EPAR/kepivance> ;
  onco:status "approved" ;
  onco:tag "nci-list", "supportive" ;
  onco:modality "Recombinant human keratinocyte growth factor" ;
  onco:approval "US 2004: Reduction of severe oral mucositis in haematological malignancies with myelotoxic therapy and autologous stem cell support", "EU 2005: Same (Kepivance)" ;
  onco:cancers <https://onco.cc/cancers/multiple-myeloma/>, <https://onco.cc/cancers/dlbcl/>, <https://onco.cc/cancers/hodgkin-lymphoma/> ;
  onco:technologies <https://onco.cc/technologies/autologous-stem-cell-transplant/> ;
  onco:companies <https://onco.cc/companies/sobi/> ;
  onco:trials <https://onco.cc/trials/nct00434161/>, <https://onco.cc/trials/nct00101582/>, <https://onco.cc/trials/nct00109031/> .